INTELLIA THERAPEUTICS, INC. (NTLA) Return on equity 2016–2025
INTELLIA THERAPEUTICS, INC. (NTLA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-61.5%FY2025 · since FY2016: -15.1% → -61.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -61.5% | -1.9 pp |
| FY2024 | -59.5% | -13.7 pp |
| FY2023 | -45.8% | -7.4 pp |
| FY2022 | -38.4% | -12.6 pp |
| FY2021 | -25.8% | -0.3 pp |
| FY2020 | -25.5% | +150.2 pp |
| FY2019 | -175.7% | -145.0 pp |
| FY2018 | -30.7% | -8.2 pp |
| FY2017 | -22.5% | -7.4 pp |
| FY2016 | -15.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More NTLA financial trends
NTLA RevenueNTLA Net incomeNTLA Net marginNTLA Gross profitNTLA Gross marginNTLA Operating incomeNTLA Operating marginNTLA Operating cash flowNTLA Free cash flowNTLA Capital expendituresNTLA Stock buybacksNTLA Dividends paidNTLA Total assetsNTLA Total liabilitiesNTLA Shareholders’ equityNTLA overview →